Heart failure & cardiomyopathies
Apixaban in Bridge to Transplant and Destination Left Ventricular Assist Device (LVAD) - Rationale and Study Design: The ApixiVAD Trial
Study context
- Population
- Patients bridged to transplant (BTT) or for destination (DT) with HeartMate 3 LVADplanned
- Participants
- 50 patients
- Planned comparison
- Apixaban as anticoagulant in HM3 LVAD patients
- Primary endpoint
- Death, thromboembolic events and major bleeding, including operative bleeding and immediate transplant outcomes
- Follow-up
- Maximum 24 months
Methodological detailsrationale and study design, pilot, multicentre, international, open-label, 1:1 randomisation, event-driven, interim analysis at 6 months, Not powered to determine non-inferiority of apixaban, Secondary outcome: quality of life related to anticoagulation, An increase in primary outcome of 20% with apixaban will be considered a signal of harm
- Rationale and study design
- Pilot
- Multicentre
- International
- Open-label
- 1:1 randomisation
- Event-driven
- Interim analysis at 6 months
- Not powered to determine non-inferiority of apixaban
- Secondary outcome: quality of life related to anticoagulation
- An increase in primary outcome of 20% with apixaban will be considered a signal of harm
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Apixaban in Bridge to Transplant and Destination LVAD - Rationale and Study Design: The ApixiVAD Trial. ESC Heart Fail. Published 22 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →